Rapt Therapeutics Stock EBITDA
| RAPT Stock | USD 32.42 1.59 5.16% |
RAPT Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting RAPT Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. RAPT Therapeutics Company EBITDA Analysis
RAPT Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current RAPT Therapeutics EBITDA | (134.9 M) |
Most of RAPT Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAPT Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, RAPT Therapeutics reported earnings before interest,tax, depreciation and amortization of (134.9 Million). This is 115.37% lower than that of the Biotechnology sector and 234.69% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.46% higher than that of the company.
RAPT EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAPT Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics of similar companies.RAPT Therapeutics is currently under evaluation in ebitda category among its peers.
RAPT Fundamentals
| Return On Equity | -0.85 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 671.59 M | ||||
| Shares Outstanding | 27.71 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 65.53 % | ||||
| Number Of Shares Shorted | 916.07 K | ||||
| Price To Book | 5.44 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M | ||||
| EBITDA | (134.9 M) | ||||
| Net Income | (129.87 M) | ||||
| Cash And Equivalents | 207.34 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 4.49 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 15.97 X | ||||
| Book Value Per Share | 9.02 X | ||||
| Cash Flow From Operations | (83.3 M) | ||||
| Short Ratio | 2.25 X | ||||
| Earnings Per Share | (11.66) X | ||||
| Target Price | 65.0 | ||||
| Number Of Employees | 60 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 854.33 M | ||||
| Total Asset | 240.32 M | ||||
| Retained Earnings | (614.55 M) | ||||
| Working Capital | 186.88 M | ||||
| Current Asset | 17 K | ||||
| Current Liabilities | 167 K | ||||
| Net Asset | 240.32 M |
About RAPT Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RAPT Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.